Image credit- shutterstock
Leading European biopharmaceutical company, Menarini Asia-Pacific, has announced the expansion of its export manufacturing hub, PT. Menarini Indria Laboratories (Milab), in Cikarang, West Java, Indonesia. This strategic milestone positions Menarini to meet growing regional demand while elevating Indonesia's role in the pharmaceutical supply chain.
With support from the Indonesian government, Milab has achieved remarkable growth. From 2023 to 2025, its total export volume for Dermatix as well as other oral solid and oral liquid pharmaceutical products more than doubled, reaching a projected cumulative total of 2.8 million units by 2025. This growth is driven by significant investments in advanced infrastructure and technology, enabling the facility to meet the increasing international demand.
As part of its commitment to responsible manufacturing and global standards, sustainability remains an integral part of Milab's journey. The facility's achievements include the prestigious Gold Flag for compliance with ISO 14001, ISO 45001, the OHS Management System with 166 Criteria, and ISO 50001 certifications. These accolades reaffirm Menarini's unwavering commitment to sustainability, workplace safety, and energy efficiency, all critical to enhancing Indonesia's growing global competitiveness in the pharmaceutical industry.
Aligned with the Golden Indonesia 2045 Vision and Indonesia's 2025-2029 National Medium-Term Development Plan, this milestone highlights the power of public-private collaboration in driving export growth and industrial innovation while elevating Indonesia's global standing.
